Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Mammary Cell News 9.48 December 7, 2017 | |
 | |
| |
TOP STORYA Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity The authors describe a robust protocol for long-term culturing of human mammary epithelial organoids. Using this protocol, >100 primary and metastatic breast cancer organoid lines were generated, broadly recapitulating the diversity of the disease. [Cell] Abstract | Graphical Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Researchers report the first discovery of naturally occurring estrogen receptor-α (ESR1)Y537C and ESR1Y537S mutations in MCF7 and SUM44 ESR1-positive cell lines after acquisition of resistance to long-term-estrogen-deprivation and subsequent resistance to fulvestrant. [Nat Commun] Full Article Scientists report a unique role for Bcl-2-associated athanogene 2 (BAG2), which is significantly overexpressed in triple-negative breast cancer, in regulating the dual functions of cathepsin B as either a pro- or anti-oncogenic enzyme. [Cell Rep] Full Article | Graphical Abstract Investigators have previously shown that xCT is highly expressed in tumorspheres derived from breast cancer cell lines and downregulation of xCT altered breast cancer stem cell function in vitro and inhibited pulmonary metastases in vivo. They further strengthened these observations by developing a virus-like-particle immunotherapy targeting the xCT protein. [Oncoimmunology] Full Article | Press Release Researchers showed by both phenotypic and functional measurements that normal human mammary progenitor cells are significantly under-represented in the mammary epithelium of patients’ tumor-adjacent tissue (TAT). Fibroblasts isolated from TAT samples showed a reduced ability to support normal EGF-stimulated mammary progenitor cell proliferation in vitro via their increased secretion of transforming growth factor β. [Stem Cell Reports] Full Article | Graphical Abstract In vivo studies demonstrated that the nanoparticle (NP)-based mRNA vaccine, targeted to mannose receptors on dendritic cells (DC), could successfully express tumor antigen in the DC of the lymph node, that the NP vaccine could induce a strong, antigen-specific, in vivo cytotoxic T lymphocyte response against triple negative breast cancer 4T1 cells, and that combination immunotherapy of the vaccine and anti-CTLA-4 monoclonal antibody could significantly enhance anti-tumor immune response compared to the vaccine or monoclonal antibody alone. [Mol Ther] Abstract | Graphical Abstract Sox2 Communicates with Tregs through CCL1 to Promote the Stemness Property of Breast Cancer Cells Scientists disclose that the primarily cultured Tregs isolated from breast-tumor-bearing Foxp3-EGFP mouse upregulate the stemness property of breast cancer cells. Tregs increased the side-population and the Aldehyde dehydrogenase-bright population of mouse breast cancer cells, promoted their sphere formation in a paracrine manner, and enhanced the expression of stemness genes, such as Sox2 and so forth. [Stem Cells] Abstract MDA-MB231 cells were submitted to selection treatment with mitoxantrone and doxorubicin. Cells submitted to this treatment exhibited a remarkable increment of NF-E2-related factor 2 (Nrf2) level, which was accompanied by upregulation of catalase, MnSOD, HSP70, Bcl-2 and P-glycoprotein. [Cell Death Dis] Full Article Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation Investigators found that caveolin-1 was over-expressed in basal-like triple-negative breast cancer (TNBC) cell lines and barely expressed in HER-2-positive cells; additionally, they observed that HER-2-positive cell lines were more sensitive to irradiation than basal-like TNBC cells. [Cell Physiol Biochem] Full Article Pristimerin showed an anti-growth effect on cancer cells and cancer stem cells with IC50 values ranging at 0.38–1.75 μM. Apoptosis was induced in MCF-7 and MCF-7s cells. [Pharmacol Res] Abstract | Graphical Abstract D2A1-m1 and D2A1-m2 were generated from the poorly metastasising BALB/c-derived D2A1 cell line by serial in vivo passaging. In vivo and in vitro analyses revealed distinct and shared characteristics of the metastatic D2A1-m1 and D2A1-m2 sublines. [Dis Model Mech] Abstract | Full Article | |
| |
| |
REVIEWSThe authors examine the relative efficacy of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) alone and in mixtures on breast cancer subtypes. The elucidation of optimal EPA:DHA ratios will be important for designing targeted n-3 long chain polyunsaturated fatty acids treatments. [Int J Mol Sci] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSThe German Breast Group and Celgene Corporation announced long-term invasive disease-free survival results from the GeparSepto clinical trial comparing the investigational use of ABRAXANE® to paclitaxel in early high-risk breast cancer patients. [Press release from Celgene Corporation discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Pfizer Inc. announced updated progression-free survival results from the Phase III PALOMA-2 trial reinforcing the clinical benefit of IBRANCE® combined with letrozole. [Press release from Pfizer Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Puma Biotechnology, Inc. will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib. [Press release from Puma Biotechnology, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Lumicell, Inc. announced the presentation of clinical data from its ongoing Phase II breast cancer trial with the LUM System, which integrates the immuno- and cancer-targeted optical agent LUM015, the Lumicell handheld imaging device and decision software to detect cancer cells in real-time during surgery. [Press release from Lumicell, Inc. (Business Wire, Inc.) discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release CASI Pharmaceuticals, Inc. announced a poster presentation on ENMD-2076. ENMD-2076 is currently in a Phase II trial for the treatment of triple-negative breast cancer. [Press release from CASI Pharmaceuticals, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Seattle Genetics, Inc. announced updated data from an ongoing Phase I clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer. [Press release from Seattle Genetics, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Zymeworks Inc. presented the completed dose escalation portion of its Phase I study of ZW25, a novel Azymetric™ bispecific antibody targeting two distinct domains of the HER2 receptor. [Press release from Zymeworks, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer Daiichi Sankyo Company, Limited announced that updated safety and efficacy data from two subgroups of patients with metastatic breast cancer from an ongoing Phase I study of DS-8201, an investigational HER2-targeting antibody drug conjugate, were presented. [Press release from Daiichi Sankyo Company, Limited (PR Newswire Association LLC.) discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Alpine Immune Sciences, Inc. announced results of a preclinical study of novel immuno-oncology molecules derived from the company’s variant immunoglobulin domain platform. [Press release from Alpine Immune Sciences, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release H3 Biomedicine Presents Preclinical Data on Novel ERα Antagonist H3 Biomedicine Inc. announced that company scientists are presenting data from preclinical studies involving H3B-6545, an oral, selective small molecule covalent antagonist of wild-type and mutant estrogen receptor (ERα). [Press release from H3 Biomedicine Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Syros Pharmaceuticals announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase I clinical trial in advanced solid tumors, demonstrate anti-tumor activity across a broad panel of breast cancer cell lines and point to potential biomarkers predictive of response. [Press release from Syros Pharmaceuticals discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Agendia, Inc. announced the presentation of extensive new data highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping Test. [Press release from Agendia, Inc. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Ambry Presents Research Expanding Our Understanding of Gene Disease Relationships Ambry Genetics Corporation is presenting data to help the medical community further understand the genetic mutations behind hereditary breast cancer, which accounts for up to 10% of all breast cancer diagnoses. [Press release from Ambry Genetics Corporation (Business Wire, Inc.) discussing research to be presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release Caris Life Sciences Announces Presentations Highlighting Precision Medicine Advances Caris Life Sciences® announced the acceptance of three abstracts, including a spotlight poster discussion and two poster sessions, for presentation. [Press release from Caris Life Sciences discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release ClearLight Diagnostics, LLC announced that it will present data. [Press release from ClearLight Diagnostics, LLC. discussing research presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS), San Antonio] Press Release | |
| |
INDUSTRY NEWSNantHealth, Inc. announced its support for a research study initiated by the University of California, San Francisco that will use NantHealth’s GPS Cancer™ panomic molecular analysis test to explore the molecular basis of patients with metastatic or recurrent breast cancer. [NantHealth Inc.] Press Release Agendia and Institute Curie in Paris, France, announce a co-validation partnership for Agendia’s new in vitro diagnostic MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit. [Agendia] Press Release Agendia and University Hospitals Leuven in Belgium have partnered to co-validate Agendia’s new in vitro diagnostic MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit. [Agendia] Press Release Novartis announced results from the Phase III MONALEESA-7 trial in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) advanced or metastatic breast cancer demonstrating Kisqali® in combination with an aromatase inhibitor or tamoxifen and goserelin as initial endocrine-based therapy significantly prolonged progression-free survival compared to endocrine therapy and goserelin alone. [Novartis AG] Press Release Mylan N.V. and Biocon Ltd. announced that the FDA has approved Mylan’s Ogivri™, a biosimilar to Herceptin®, co-developed with Biocon. [Mylan N.V.] Press Release Oncolytics Biotech® Inc. announced that the company has received a favorable Final Advice Letter from the European Medicines Agency. The Letter refers to the proposed use of pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative metastatic breast cancer patients in a pivotal Phase III registration study and suggests that a single 400-patient study may be acceptable to form the basis of a Marketing Authorization Application in Europe. [Oncolytics Biotech, Inc.] Press Release Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant Eagle Pharmaceuticals, Inc. announced that it has begun dosing subjects in its pivotal study for the company’s fulvestrant formulation intended as a monotherapy treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. [Eagle Pharmaceuticals, Inc.] Press Release | |
| |
POLICY NEWSUS Graduate Students in Uproar over Proposed Tax Hike Many US universities waive tuition for students who conduct research or teach. But a provision in a tax bill passed by the US House of Representatives would add that tuition to students’ taxable income. [Nature News] Editorial Hundreds of German Universities Set to Lose Access to Elsevier Journals Around 200 German universities will lose their subscriptions to Elsevier journals within weeks, because negotiations have failed to end a long-term contract dispute. [Nature News] Editorial Trump Science Job Nominees Missing Advanced Science Degrees When it comes to filling jobs dealing with complex science, environment, and health issues, the Trump administration is nominating people with fewer science academic credentials than their Obama predecessors. And it’s moving slower as well. [STAT News] Editorial Biohackers Disregard FDA Warning on DIY Gene Therapy Despite a warning from the federal government about do-it-yourself (DIY) gene therapy, two companies say they’ll continue offering DNA-altering materials to the public. The companies, The Odin and Ascendance Biomedical, both recently posted videos online of people self-administering DNA molecules their labs had produced. [MIT Technology Review] Editorial
| |
EVENTSNEW 11th Dutch Stem Cell Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Professor – Tenure System – Cancer Biology (Michigan State University) Postdoctoral Associate – Breast Cancer Research (University of Miami) Postdoctoral Associate – Melanoma and Breast Cancer Research (University of Miami) Cancer Bioinformatician – Breast Cancer Research (Institute of Cancer Research) Postdoctoral Research Scientist/Fellow – Breast Cancer (Columbia University) Postdoctoral Positions – Breast Cancer (Northwestern University – Feinberg School of Medicine) Physician Scientist – Translational Research in Breast Cancers (University of New Mexico) Postdoctoral Fellowship – Breast Cancer Research (Geisel School of Medicine at Dartmouth) Postdoctoral Position – Transcriptomics and Cancer Epigenetics (Universität Basel) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
